ONCOLOGY Nurse Edition Vol 24 No 2 | Oncology Nurse Edition

PARP* Inhibitors in BRCA-Associated Cancers

February 18, 2010

None; investigational agents olaparib (AZD2281) and BSI-201 are in phase I and II clinical trials; other PARP inhibitors under investigation include AGO 14699 (Pfizer), ABT-888 (Enzo), and MK4827 (Merck).

Coping With ‘Chemobrain’

February 16, 2010

Cognitive impairment, including memory loss, inability to concentrate, and difficulty multitasking, has become a widely recognized possible late effect of chemotherapy and cancer treatment.